Category: Schrodinger
-
Schrodinger gets rights to cancer drug candidate back from Bristol
•
koto_feja Bristol-Myers Squibb (New York Stock Exchange: BMI) Rights to its preclinical cancer drug candidate, an SOS1 inhibitor, have been returned to Schrödinger (Nasdaq:SDGR). Schrödinger noted that he had submitted a candidate for development, and Bristol was conducting IND-enabled studies on it. The two companies Their collaboration began in 2020,…